Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions: Exercise Therapy; Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Hartford, Connecticut + 7 more

Conditions: Prostate Cancer
Interventions: Low fat diet, Lower carbohydrate diet; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: STM-416p; Drug
Lead sponsor: SURGE Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tucson, Arizona • Gainesville, Florida

Conditions: Cancer
Interventions: capecitabine, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more

Conditions: Prostate Cancer
Interventions: Ibrance, Bicalutamide, Zoladex, Lupron Depot; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions: RYZ711, PSMA PET/CT; Drug · Diagnostic Test
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: lapatinib, paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Resectable Localized Prostate Cancer
Interventions: Hydroxychloroquine Sulfate 400Mg Tab, Placebo; Drug
Lead sponsor: Lionel.D.Lewis, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer, Osteoporosis, Hypogonadism
Interventions: alendronate; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 85 Years · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: ST101, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Sapience Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more

Conditions: Prostate Cancer
Interventions: therapeutic autologous dendritic cells; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostatic Neoplasms
Interventions: Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Interventions: CyberKnife SBRT; Radiation
Lead sponsor: Crozer-Keystone Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: GM-CSF gene transduced allogeneic vaccine GVAX; Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Prostatic Neoplasms
Interventions: PROSTVAC; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
Interventions: Pioglitazone 30 mg, Placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: Curcumin, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 89 Years · Male only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Breast Cancer, Advanced Prostate Cancer, Advanced Lung Cancer, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: ENGAGE, Supportive Care; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: calcitriol, mitoxantrone hydrochloride, prednisone; Dietary Supplement · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: ABBV-969; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Akt Inhibitor MK2206, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Search by objective public record fields.

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

RYZ711 Diagnostic Platform Study

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

HCQ in Resectable Localized Prostate Cancer

Prevention of Osteoporosis in Men With Prostate Cancer

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

CyberKnife Dose Escalation Prostate Cancer Trial

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Ambulatory Cancer Pain Management: A Feasibility Study

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Pioglitazone and Insulin Resistance in ADT

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

Engage Psychosocial Intervention for Cancer Symptoms

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer